To extend these finding, using TIDE (Tumor Immune Dysfunction and Exclusion), we analyzed the relationship between survival fraction and cytotoxic T lymphocyte (CTL) levels in two patient groups: CDC20-low and CDC20-high (Additional file 2: Fig. S4, Additional file 1: Table S8). This evidence concerns the gene CDC20 and neoplasm.